title: Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia.
abstract: The protein tyrosine phosphatase SHP-1 dephosphorylates BCR-ABL1, thereby serving as a potential control mechanism of BCR-ABL1 kinase activity. Pathways regulating SHP-1 expression, which could be exploited in the therapeutics of TKI-resistant chronic myeloid leukemia (CML), remain unknown. Moreover, the questions of whether there is any kind of SHP-1 deregulation in CML, contributing to disease initiation or evolution, as well as the question of prognostic significance of SHP-1, have not been definitively answered. This study shows moderately lower SHP-1 mRNA expression in chronic phase CML patients in comparison to healthy individuals and no change in SHP-1 mRNA levels after successful TKI treatment. Mutational analysis of the aminoterminal and phosphatase domains of SHP-1 in patients did not reveal genetic lesions. This study also found no correlation of SHP-1 expression at diagnosis with response to treatment, although a trend for lower SHP-1 expression was noted in the very small non-responders' group of the 3-month therapeutic milestone.
authors.affiliation: a Hematology Unit, 1st Department of Internal Medicine, Laiko Hospital , University of Athens , Athens , Greece ;
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Papadopoulou
authors.affiliation: a Hematology Unit, 1st Department of Internal Medicine, Laiko Hospital , University of Athens , Athens , Greece ;
authors.forename: Elina
authors.initials: E
authors.lastname: Kontandreopoulou
authors.affiliation: b Molecular Hematology Laboratory, 1st Department of Propaedeutic Medicine , University of Athens , Athens , Greece ;
authors.forename: Panayiotis
authors.initials: P
authors.lastname: Panayiotidis
authors.affiliation: b Molecular Hematology Laboratory, 1st Department of Propaedeutic Medicine , University of Athens , Athens , Greece ;
authors.forename: Maria
authors.initials: M
authors.lastname: Roumelioti
authors.affiliation: c Hematology Department, Laiko Hospital , University of Athens , Athens , Greece ;
authors.forename: Maria
authors.initials: M
authors.lastname: Angelopoulou
authors.affiliation: d Hematology Department , University of Ioannina Medical School , Ioannina , Greece ;
authors.forename: Lydia
authors.initials: L
authors.lastname: Kyriazopoulou
authors.affiliation: a Hematology Unit, 1st Department of Internal Medicine, Laiko Hospital , University of Athens , Athens , Greece ;
authors.forename: Panagiotis T
authors.initials: PT
authors.lastname: Diamantopoulos
authors.affiliation: a Hematology Unit, 1st Department of Internal Medicine, Laiko Hospital , University of Athens , Athens , Greece ;
authors.forename: George
authors.initials: G
authors.lastname: Vaiopoulos
authors.affiliation: a Hematology Unit, 1st Department of Internal Medicine, Laiko Hospital , University of Athens , Athens , Greece ;
authors.forename: Eleni
authors.initials: E
authors.lastname: Variami
authors.affiliation: e Hematology Department , Democritus University of Thrace Medical School , Xanthi , Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kotsianidis
authors.affiliation: a Hematology Unit, 1st Department of Internal Medicine, Laiko Hospital , University of Athens , Athens , Greece ;
authors.forename: Nora
authors.initials: N
authors.lastname: Athina Viniou
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009154:Mutation; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6 / Q000235:genetics*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6
keywords: Protein tyrosine phosphatases; SHP-1; chronic myeloid leukemia; major molecular response